So we are going to make it very clear now and offer clear guidance with Humira. The Humira example that you described, let's be honest about what's going on. Sometimes the branded biologic manufacturer is paying the PBM to make sure that biosimilars are not added to that formulary. We're calling for increased transparency. You can see we talk every day. We talk all the time. This is a top priority for Dr. Oz to increase transparency and to make biosimilars a priority. (25:11–25:22)
CLAIM
Asserts that branded biologic manufacturers sometimes pay PBMs to exclude biosimilars from formularies.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
_(cropped).png)